UNSPSC 51421906: Locicortolone dicibate

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G87210HO7A. European Medicines Agency schedules Locicortolone dicibate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08546MIG. Locicortolone dicibate generally arises in the molecular formula C36H50CL2O5. The term LOCICORTOLONE DICIBATE is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule locicortolone dicibate under HS 29372200 and SITC 54153.

UNSPSC 51421906 Locicortolone dicibate is a Commodity code that state and local governments are using to tag pharmaceutical procurement, though recent activity shows a significant mismatch between the code's nominal scope and the work actually being solicited. The code appears in two recent state and local opportunities: Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, response due July 26, 2023), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026). Neither opportunity involves locicortolone dicibate as a pharmaceutical product. The Seminole County procurement is a straightforward supply contract for naloxone kits and safe drug deactivation equipment to support community health initiatives, with annual quantities of 1,900 units of naloxone and 800 deactivation systems delivered quarterly. The Texas HHS RFI, by contrast, is exploratory market intelligence gathering aimed at understanding vendor capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers, with no formal evaluation criteria or award values specified at this stage. Issuing bodies include state health and human services agencies and county health departments.

Activity in this code spans at least Florida and Texas, with Seminole County representing a county-level health purchaser and the Texas HHS Commission representing a state-level pharmacy benefit administrator. The Seminole County IFB (solicitation IFB60459723LAS) requires bidders to provide unit costs, comply with drug-free workplace certification and E-Verify, and maintain workers' compensation and commercial general liability insurance; the contract carries a two-year initial term with one-year renewal option and a three-month probationary termination clause. The Texas RFI (HHS0017013) does not establish a binding timeline or award structure, instead seeking vendor responses on direct-contracting capabilities, volume fulfillment strategies, and outcomes-based pricing models to inform the state's future formal procurement strategy. Neither opportunity specifies set-aside designations or disadvantaged-enterprise restrictions. The code shows limited and misaligned recent activity for a targeted pharmaceutical ingredient; practitioners should verify whether the code mismatch reflects a classification error or whether state and local procurement systems are broadly tagging pharmacy-related activity under this Commodity code despite nominal scope divergence.